BCR / ABL – Qualitative

Description

**BCR / ABL – Qualitative Lab Test**

The BCR / ABL – Qualitative test is a specialized diagnostic tool designed to detect the presence of the BCR-ABL fusion gene, a genetic abnormality commonly associated with certain types of leukemia, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). This test plays a critical role in diagnosing and monitoring these conditions, helping healthcare providers develop effective treatment plans.

### Why You Need This Test
The BCR / ABL – Qualitative test is essential for individuals suspected of having leukemia or those undergoing treatment for CML or ALL. The BCR-ABL fusion gene results from a chromosomal abnormality known as the Philadelphia chromosome, which leads to the production of an abnormal protein that drives uncontrolled cell growth. Early detection of this genetic marker is crucial for accurate diagnosis, timely intervention, and effective disease management. Additionally, this test is used to monitor treatment response and detect minimal residual disease, ensuring that therapy is working as intended.

### Symptoms That Indicate This Test
You may need the BCR / ABL – Qualitative test if you experience symptoms commonly associated with leukemia, such as:
– Persistent fatigue or weakness
– Unexplained weight loss
– Frequent infections
– Easy bruising or bleeding
– Night sweats
– Bone or joint pain
– Enlarged spleen or lymph nodes
– Shortness of breath

If you have been diagnosed with leukemia, this test is also recommended to monitor your condition and evaluate the effectiveness of your treatment.

### Natural Production
Under normal circumstances, the body does not produce the BCR-ABL fusion gene. This genetic abnormality arises from a translocation between chromosomes 9 and 22, forming the Philadelphia chromosome. The resulting BCR-ABL gene produces an abnormal tyrosine kinase protein that disrupts normal cell regulation, leading to the uncontrolled proliferation of white blood cells. Factors such as genetic predisposition or exposure to certain environmental triggers may increase the risk of developing this chromosomal abnormality.

### What Happens If Untreated
If the BCR-ABL fusion gene is not detected and treated, the associated leukemia can progress rapidly, leading to severe health complications. Untreated CML may advance from a chronic phase to an accelerated or blast phase, where the disease becomes more aggressive and harder to treat. Similarly, untreated ALL can lead to life-threatening complications, including organ damage, severe infections, and bone marrow failure. Early detection through the BCR / ABL – Qualitative test is vital to prevent these outcomes and improve survival rates.

### How to Prepare for the Test
Preparation for the BCR / ABL – Qualitative test is straightforward. No fasting or special dietary restrictions are required. However, it is important to inform your healthcare provider about any medications or supplements you are taking, as these may influence test results. Follow any additional instructions provided by your doctor or the testing facility to ensure accurate results.

### Test Overview
– **Sample Type**: Whole Blood
– **Methodology**: Real-time PCR (Polymerase Chain Reaction)
– **Turnaround Time (TAT)**: 14 Days

This molecular diagnostic test uses advanced real-time PCR technology to detect the presence of the BCR-ABL fusion gene with high sensitivity and specificity. Results are typically available within 14 days, providing timely insights for diagnosis and treatment planning.

### Call to Action
Take control of your health today by scheduling the BCR / ABL – Qualitative test. Whether you are seeking a diagnosis or monitoring your treatment progress, this test provides critical information to guide your healthcare journey. Book your lab test online now and find a diagnostic test near you to ensure peace of mind and proactive health management.

**Category**: Molecular